Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or
- Company Now Exclusively Focused on Development and Commercialization of Abecma - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin , Chief Investment Officer, and Founder of Casdin Capital , and Charles Newton , Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the
The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 PRINCETON, N.J. & CAMBRIDGE, Mass.
New strategic path forward as Abecma- focused company announced in January 2024 ; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024 , to review data supporting the
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024 . A conference call and webcast will be held at 8:00 a.m. ET . Members of the management team will also be presenting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference , the St.
PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2024-- Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the
- Company to focus exclusively on commercialization and development of Abecma , in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Gregory - Chip Baird named
